Research summary, original research, 2015

Effect of Vascular Access Site Choice on Radiation Exposure During Coronary Angiography: The REVERE Trial (Randomized Evaluation of Vascular Entry Site and Radiation Exposure)

Pancholy SB, Joshi P, Shah S, Rao SV, Bertrand OF, Patel TM. JACC. Cardiovascular interventions. 2015

Read the original paper

In plain language

In a randomized trial of 1,493 diagnostic coronary angiograms, patient radiation dose was similar with femoral, left radial and right radial access, but operators received a slightly higher median dose with left radial access.

At a glance

Type of study
Original research, Randomized trial
Who was studied
Patients, Interventional cardiologists
Size
n = 1,493 patients
Summary based on
the abstract

What it found

  • Left radial access was associated with higher median operator exposure than femoral or right radial access.

    Key figures: Left radial access (LRA) 3 mrem [interquartile range (IQR) 2 to 5], p = 0.001 vs. FA, p = 0.0001 vs. Right radial access (RRA); FA 2 mrem [IQR 2 to 4]

  • Patient air kerma did not differ significantly among femoral, left radial and right radial access.

    Key figures: medians FA 421 mGy, LRA 454 mGy, RRA 483 mGy, p = 0.146

  • Dose-area product did not differ significantly among access sites.

    Key figures: medians FA 25.5, LRA 26.6, RRA 27.7 Gy cm(2), p = 0.40

  • Fluoroscopy time was similar across access sites.

    Key figures: median 1.3 min FA and LRA, 1.32 min RRA, p = 0.19

Limits to keep in mind

Single tertiary center, diagnostic angiography only; operator dose differences are small in absolute terms and measured per procedure by dosimeter rather than as health outcomes. Abstract only, so dosimeter placement and operator details are not described.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.